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BACKGROUND: Previous studies have shown that more than 20% of laboratories would have recommended inaccurate doses of Rh immune globulin (RhIG) in hypothetical cases. Efforts have been made in educating laboratories in correct dosing calculations; however, obstetricians are most often responsible for ordering RhIG. The objective of this study was to assess knowledge of RhIG indications and dosing among obstetrics and gynecology (OB/GYN) physicians in the United States.
STUDY DESIGN AND METHODS: An anonymous
17-question online survey was distributed to all OB/GYN resident and attending physicians affiliated with US residency training programs.
RESULTS:
A total of 165 surveys were collected, with 139 fully completed. Ninety-two percent of respondents correctly recognized the need for RhIG in D-patients with negative antibody screens. In a scenario of a fetomaternal hemorrhage (FMH) of 45 mL, only 22% of respondents correctly chose the appropriate RhIG dosage. Of those who were correct, 10% had correctly identified 30 mL as the amount of fetal whole blood covered by one dose of RhIG, while 48% incorrectly identified 15 mL (n 5 31). A total of 49.3% of respondents reported residency as the most recent formal training on RhIG dosing and 35% reported never (n 5 140).
CONCLUSIONS:
Our study found that OB/GYN physicians are knowledgeable regarding indications for RhIG immunoprophylaxis but were insufficient at calculating dosages in cases of FMH. More standardized education and training among OB/GYN physicians may decrease the risk of maternal alloimmunization, in part because RhIG dosage recommendations from laboratories are not standard practice. R h immune globulin (RhIG) contains high-titered immunoglobulin (Ig)G D antibodies and is used to prevent maternal alloimmunization to the D blood group antigen. RhIG is administered antepartum in pregnancies at risk of Rh alloimmunization, where the mother is D-and the father is D1 or in cases where the Rh status of the father is unknown. RhIG is also given after delivery in cases where a D1 infant was born to a D-mother. The major cause of maternal Rh alloimmunization is from fetomaternal hemorrhage (FMH) during delivery, with other causes being abdominal trauma, ectopic pregnancy, and invasive obstetrical procedures. 1 Future pregnancies in mothers with Rh alloimmunization are at risk for developing hemolytic disease of the fetus and newborn, which is associated with significant morbidity and mortality.
The American College of Obstetricians and Gynecologists (ACOG) recommends a single dose of 300 mg of RhIG at 28 weeks of gestation for women at risk of Rh alloimmunization. ACOG also recommends that all D-women who deliver D1 infants be screened for possible FMH after delivery using the rosette test. 2 
MATERIALS AND METHODS
A secure online-based survey created through LimeSurvey (LimeSurvey Partners) 9 was distributed electronically to all obstetrician and gynecologist (OB/GYN) attending and resident physicians affiliated with residency training programs in the United States through the OB/GYN Residency Coordinator Listerv. The survey was anonymous and consisted of 17 questions that asked four categories of questions related to RhIG management. The full survey can be seen in Appendix S1 (available as supporting information in the online version of this paper). This study was determined to be exempt by the institutional review board of the University of Vermont. Participation in the study was voluntary. No identifying information was collected. First, respondents were asked to report self-perceived knowledge and comfort with management of Rh immunoprophylaxis. Next, respondents were asked to answer specific questions testing medical indications for RhIG therapy and dosing calculations for various clinical scenarios. No restrictions were placed on the use of resources to assist respondents with completing the survey. Respondents were then asked questions about the standard practice of RhIG dosing calculations at their respective hospitals. Finally, respondents were asked to identify when they received formal training on the indications and dosing calculations for Rh immunoprophylaxis. Certain demographic information was gathered: current year in training or practice, generalist or specialist, and the nature of the practice (academic/university, hospital-based, private practice).
Before implementation, the survey was screened by peer review and reviewed by a small group of fellows and attendings in OB/GYN. After minor edits, the survey was distributed. The survey was released electronically and respondents were given 5 months to respond before results were collected. Respondents were allowed to save and resume the survey. A formal token process was not utilized. Reminder e-mails were sent three times. Incomplete surveys were included for questions for which there were responses. Missing data points were excluded from the individual question analysis and calculation of percent responses was based on completed responses per question. For all analyses, responses from fellows were categorized with residents. Correct answers for clinical scenarios of excess FMH were calculated using AABB Technical Manual RhIG dosing guidelines and confirmed with the College of American Pathologists online RhIG calculator. Fisher's exact tests were performed to compare survey responses between groups with computer software (Stata, Version 13, StataCorp).
RESULTS
Survey links were sent to 201 program coordinators at OB/GYN residency training programs in the United States. A total of 165 surveys were collected, of which 139 were fully completed. The majority of respondents were OB/ GYN residents (82%) and the remainder were fellows (2%) and attending physicians (16%; n 5 139; Table 1 ). Of attending physicians, 50% were primarily generalists, 36% OB specialists, and 14% GYN specialists. Eighty-two percent of attending physicians practiced at an academic/ university-based practice, 5% at a hospital-based practiced, and 14% in private practice. The majority of respondents (83%) believed RhIG to be "very safe" and the majority (76%) believed RhIG to be "very effective" (n 5 151).
All attending physicians reported to be moderately to extremely knowledgeable about indications for Rh immunoprophylaxis. Resident physicians reported a wide range of knowledge level of indications for RhIG ( Table 2 ). The majority of respondents (61%) reported residency to be the most recent formal training on RhIG indications, while 26% reported medical school, 1% reported fellowship, and 12% reported never receiving formal training on RhIG indications (n 5 140). Ninety-two percent of respondents correctly recognized the need for RhIG in D-patients with negative antibody screens, but 34% incorrectly reported the need for RhIG in a D-patient who was already sensitized as evidenced by having anti-D detectable on the antibody screen (n 5 146; Table 3 ). All 22 attending physicians answered this question correctly. Forty-nine percent of residents with incorrect responses to this question reported to be moderately or extremely knowledgeable about indications for RhIG immunoprophylaxis (n 5 47). The majority of respondents identified the correct time intervals for RhIG administration: 96% at 28 weeks' gestation and 95% within 72 hours of delivery of a D1 infant (n 5 146).
Ninety-one percent of attending physicians and 31% of resident physicians reported to be at least moderately knowledgeable about giving the proper dosage of RhIG (Table 2) . Forty-nine percent of respondents reported residency to be their most recent formal training on RhIG dosing, while 14% reported medical school, 2% reported fellowship, and 35% reported never receiving formal training on dosing of RhIG (n 5 140). Seventy-eight percent of respondents correctly identified the standard dosage of 300 mg of RhIG (n 5 140). Fifty-four percent of respondents correctly identified 30 mL of fetal whole blood as the volume of FMH that a single 300-mg vial of RhIG will suppress alloimmunization against, while 23% incorrectly reported 15 mL of fetal whole blood and the remaining 23% reported incorrect values ranging from 1 to 200 mL (n 5 87). Among attending physicians, 64% correctly identified 30 mL as the volume of fetal whole blood covered by one dose of RhIG, while 18% incorrectly answered 15 mL (n 5 22).
There were three questions about RhIG dosing calculations for clinical scenarios of FMH of 0, 15, and 45 mL. Eighty-two percent of respondents correctly chose the appropriate dosage of one vial of RhIG for a FMH of 0 mL, while 10% selected "do not know" and 8% answered incorrectly (n 5 140). Those who reported being at least moderately knowledgeable about RhIG dosage were significantly more likely to answer the FMH of 0 mL scenario correctly (p 5 0.002). In a scenario of a FMH of 15 mL, 9% of respondents correctly chose the appropriate dosage of two vials of RhIG while 21% selected "do not know" and 70% answered incorrectly (n 5 140). In a scenario of a FMH of 45 mL, 22% of respondents answered correctly (three vials) while 25% selected "do not know" and 53% answered incorrectly (n 5 140; Table 4 ). Those who reported being at least moderately knowledgeable about RhIG dosage were not significantly more likely to answer the excess FMH scenario questions correctly (p 5 0.51 for FMH of 15 mL; p 5 0.32 for FMH of 45 mL). For these scenarios, the correct response rate was similar among residents (9% correct for FMH of 15 mL; 23% correct for FMH of 45 mL) and attending physicians (9% correct for FMH of 15 mL; 18% correct for FMH of 45 mL). Attending physicians were not significantly more likely than residents to correctly answer scenarios of a FMH of 15 mL (p 5 1.00) or FMH of 45 mL (p 5 0.78). Forty-six percent of respondents reported the blood bank or transfusion service usually determines the dosage of RhIG in cases of FMH, 9% reported the obstetric provider themselves, and 24% did not know (n 5 140; Table  5 ). The two attending physicians who reported determining the RhIG themselves both practiced at an academic or university-based setting. None of those who reported determining the RhIG themselves answered all three dosages questions correctly. The majority of respondents (52%) did not know the standard unit of measurement for FMH given by their hospital laboratory: 29% reported milliliters, 8% reported percentage of maternal blood volume, and 11% reported both (n 5 140). (http://www.cap.org/web/home/involved/council-committees/transfusion-medicine-topic-center). Many obstetricians we surveyed reported their blood banks as being responsible for dosage calculation in cases of FMH, although 9% continue to calculate dosages themselves. In settings where another service determines the dosage, it remains incumbent on the ordering provider, who is ultimately responsible for the patient, to be able to confirm that the recommended dosage is correct, especially given the poor performance of hospital laboratories in prior studies.
We found that a significant percentage of OB/GYN physicians have not received formal training on calculating RhIG dosing in cases of FMH and demonstrated poor knowledge in this area. Resident physicians were more likely to provide incorrect responses; however, there were many deficiencies even among attending physicians. Of note, ACOG Practice Bulletin #4, "Prevention of Rh D Alloimmunization," discusses the indications for RhIG but does not provide information on dose calculation in cases of FMH.
2 Dose calculation for RhIG in cases of FMH is also not identified as an educational objective in the ACOG Council on Resident Education in Obstetrics and Gynecology (CREOG) Core Curriculum in Obstetrics and Gynecology. 10 In our survey there was no consistency between respondents who correctly answered that one vial of RhIG covers a FMH of 30 mL of fetal whole blood and those who correctly answered the clinical scenario questions for FMH of 15 and 45 mL, suggesting that although the respondents understood basic dosing, they were not aware of the recommendation for administration of an additional vial of RhIG in cases of excess FMH. Only 8 and 6% of those who correctly identified 30 mL as the volume of fetal whole blood covered by a single dose of RhIG gave the correct dose of RhIG for FMH of 15 and 45 mL, respectively (n 5 48). In both scenarios, 98% of those who were incorrect selected one vial less than the dose recommended by the AABB Technical Manual (n 5 44 for FMH 15 mL; n 5 45 for FMH 45 mL).
The need for further clarification and education regarding dosage recommendations can be most precisely demonstrated by the following survey response. An attending physician of 11 to 20 years, who reports to calculate RhIG dosage him-or herself, correctly identified 30 mL as the amount of fetal blood one dose covers, but incorrectly recommended a lower dosage in a FMH of 45 mL after having correctly identified the dosage for FMH of 0 and 15 mL. Although large FMH requiring more than one dose of RhIG only occurs in three of 1000 A significant limitation of our study is the unknown survey response rate. It was likely very low given the number of programs to which we distributed the survey. Our results should be interpreted with some degree of caution as they are subject to selection bias. It is plausible, however, that we are actually underestimating the knowledge deficits of OB/GYN providers, as the participants who chose to complete the survey may have felt more confident in their knowledge of RhIG indications and dosing. Of 165 respondents who began the survey, only 139 (84%) completed all the questions. Future study in this area is necessary to confirm our findings.
Additional limitations of the study may arise from nonspecific language in several of the survey questions.
Although survey questions were pilot tested before distribution and responses were examined for internal consistency, our survey was not otherwise rigorously validated. The question stems in the FMH scenarios did not include specific language to distinguish milliliters of fetal whole blood from fetal RBCs. Additionally, in the first RhIG indications question, the patients with antibody screens positive for anti-D could have been due to previous RhIG administration. Although not specifically examined, whether OB/GYN providers are aware of the distinction between anti-D due to RhIG or anti-D with no history of RhIG would be important to understand. It is also not known whether blood banks routinely report these results with sufficient information to allow for OB/GYN providers to make this distinction.
Our survey included only a limited amount of demographic information. We did not identify which programs or practices the respondents are from or where they received training in Rh immunoprophylaxis. A larger study with more demographic data may help elicit whether there are variations in responses in different regions in the country or among different types of training programs (university vs. community based). This study was limited to OB/GYN physicians, but future research could include other providers who may manage pregnant patients such as family medicine physicians, midwives, and emergency medicine physicians.
